Literature DB >> 16622219

The 6-kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of gamma interferon.

Abebech Demissie1, Liya Wassie, Markos Abebe, Abraham Aseffa, Graham Rook, Alimuddin Zumla, Peter Andersen, T Mark Doherty.   

Abstract

It is well known that the majority of healthy individuals exposed to Mycobacterium tuberculosis do not become clinically ill. We have previously shown that in recently exposed healthy contacts of tuberculosis (TB) patients, a strong immune response to the M. tuberculosis 6-kDa early secreted antigenic target (ESAT-6) virulence factor correlated with a higher risk of subsequent disease, although the mechanism was unclear at that time. Inspired by recent reports that elevated expression of interleukin-4 (IL-4) in health care workers exposed to M. tuberculosis also correlated with a higher risk of their subsequently developing disease, we examined expression of IL-4, its competitive antagonist IL-4delta2, and gamma interferon (IFN-gamma) in healthy household contacts of TB patients from Ethiopia. We then compared cytokine expression to their recognition of ESAT-6 (which is largely restricted to members of the tuberculosis complex and which serves as a reliable marker of infection) or to Ag85A (an antigen that is conserved among the mycobacteria and serves as a nonspecific control). Our study shows that in these recently exposed individuals, there is a correlation between a strong response to ESAT-6 and elevated expression of IL-4. Further, elevated expression of IL-4 is associated with lower expression of its antagonistic splice variant IL-4delta2 and with the Th1 cytokine IFN-gamma, suggesting that in these at-risk individuals, immunity is skewed away from a protective Th1 response, even before the development of clinical symptoms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16622219      PMCID: PMC1459691          DOI: 10.1128/IAI.74.5.2817-2822.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

Review 1.  Epidemiology of tuberculosis.

Authors:  Michael F Iademarco; Kenneth G Castro
Journal:  Semin Respir Infect       Date:  2003-12

2.  Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis.

Authors:  Claudia Manca; Michael B Reed; Sherry Freeman; Barun Mathema; Barry Kreiswirth; Clifton E Barry; Gilla Kaplan
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

Review 3.  Tuberculosis and HIV: a partnership against the most vulnerable.

Authors:  Pedro Cahn; Hector Perez; Graciela Ben; Claudia Ochoa
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2003 Jul-Sep

4.  Increased expression of mRNA encoding interleukin (IL)-4 and its splice variant IL-4delta2 in cells from contacts of Mycobacterium tuberculosis, in the absence of in vitro stimulation.

Authors:  Helen A Fletcher; Patrick Owiafe; David Jeffries; Philip Hill; Graham A W Rook; Alimuddin Zumla; T Mark Doherty; Roger H Brookes
Journal:  Immunology       Date:  2004-08       Impact factor: 7.397

5.  Increased Interleukin-4 production by CD8 and gammadelta T cells in health-care workers is associated with the subsequent development of active tuberculosis.

Authors:  Diane J Ordway; Leonor Costa; Marta Martins; Henrique Silveira; Leonard Amaral; Maria J Arroz; Fernando A Ventura; Hazel M Dockrell
Journal:  J Infect Dis       Date:  2004-07-13       Impact factor: 5.226

6.  Intracellular expression of interleukin-4 and interferon-gamma by a Mycobacterium tuberculosis antigen-stimulated CD4+ CD57+ T-cell subpopulation with memory phenotype in tuberculosis patients.

Authors:  Maria C Jiménez-Martínez; Marisela Linares; Renata Báez; Luis F Montaño; Salvador Martínez-Cairo; Patricia Gorocica; Raúl Chávez; Edgar Zenteno; Ricardo Lascurain
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

7.  A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response.

Authors:  Michael B Reed; Pilar Domenech; Claudia Manca; Hua Su; Amy K Barczak; Barry N Kreiswirth; Gilla Kaplan; Clifton E Barry
Journal:  Nature       Date:  2004-09-02       Impact factor: 49.962

8.  Inhibition of IFN-gamma-induced class II transactivator expression by a 19-kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasion.

Authors:  Rish K Pai; Marilyn Convery; Thomas A Hamilton; W Henry Boom; Clifford V Harding
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

9.  Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2.

Authors:  Abebech Demissie; Markos Abebe; Abraham Aseffa; Graham Rook; Helen Fletcher; Alimuddin Zumla; Karin Weldingh; Inger Brock; Peter Andersen; T Mark Doherty
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

10.  Correlates of protective immune response in tuberculous pleuritis.

Authors:  Kripa V Jalapathy; C Prabha; Sulochana D Das
Journal:  FEMS Immunol Med Microbiol       Date:  2004-03-08
View more
  16 in total

1.  Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment.

Authors:  Rhea N Coler; Sylvie Bertholet; Samuel O Pine; Mark T Orr; Valerie Reese; Hillarie Plessner Windish; Charles Davis; Maria Kahn; Susan L Baldwin; Steven G Reed
Journal:  J Infect Dis       Date:  2012-08-13       Impact factor: 5.226

2.  Is interleukin-4delta3 splice variant expression in bovine tuberculosis a marker of protective immunity?

Authors:  Shelley G Rhodes; Jason Sawyer; Adam O Whelan; Gillian S Dean; Michael Coad; Katie J Ewer; Andreas S Waldvogel; Anthony Zakher; Derek J Clifford; R Glyn Hewinson; H Martin Vordermeier
Journal:  Infect Immun       Date:  2007-03-26       Impact factor: 3.441

3.  Serum protein profiling of smear-positive and smear-negative pulmonary tuberculosis using SELDI-TOF mass spectrometry.

Authors:  Qi Liu; Xuerong Chen; Chaojun Hu; Renqing Zhang; Ji Yue; Guihui Wu; Xiaoping Li; Yunhong Wu; Fuqiang Wen
Journal:  Lung       Date:  2009-12-09       Impact factor: 2.584

4.  Longitudinal tracking of cytokines after acute exposure to tuberculosis: association of distinct cytokine patterns with protection and disease development.

Authors:  Rabia Hussain; Najeeha Talat; Firdaus Shahid; Ghaffar Dawood
Journal:  Clin Vaccine Immunol       Date:  2007-10-10

Review 5.  Effect of Helicobacter pylori and Helminth Coinfection on the Immune Response to Mycobacterium tuberculosis.

Authors:  Javier Andrés Bustamante-Rengifo; Miryam Astudillo-Hernández; María Del Pilar Crespo-Ortiz
Journal:  Curr Microbiol       Date:  2021-07-12       Impact factor: 2.188

6.  Identification of compounds that decrease numbers of Mycobacteria in human macrophages in the presence of serum amyloid P.

Authors:  Wang Xiang; Nehemiah Cox; Richard H Gomer
Journal:  J Leukoc Biol       Date:  2017-08-02       Impact factor: 4.962

7.  The immune response to tuberculosis infection in the setting of Helicobacter pylori and helminth infections.

Authors:  S Perry; A H Chang; L Sanchez; S Yang; T D Haggerty; J Parsonnet
Journal:  Epidemiol Infect       Date:  2012-09-07       Impact factor: 2.451

8.  Modulation of cell death by M. tuberculosis as a strategy for pathogen survival.

Authors:  Markos Abebe; Louise Kim; Graham Rook; Abraham Aseffa; Liya Wassie; Martha Zewdie; Alimuddin Zumla; Howard Engers; Peter Andersen; T Mark Doherty
Journal:  Clin Dev Immunol       Date:  2011-01-04

9.  Biomarker changes associated with Tuberculin Skin Test (TST) conversion: a two-year longitudinal follow-up study in exposed household contacts.

Authors:  Rabia Hussain; Najeeha Talat; Firdaus Shahid; Ghaffar Dawood
Journal:  PLoS One       Date:  2009-10-14       Impact factor: 3.240

10.  Role of TNF-Alpha, IFN-Gamma, and IL-10 in the Development of Pulmonary Tuberculosis.

Authors:  Yone Vila Nova Cavalcanti; Maria Carolina Accioly Brelaz; Juliana Kelle de Andrade Lemoine Neves; José Candido Ferraz; Valéria Rêgo Alves Pereira
Journal:  Pulm Med       Date:  2012-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.